article thumbnail

India’s contract manufacturing gains momentum due to high quality & cost effectiveness: Expert

AuroBlog - Aurous Healthcare Clinical Trials blog

India is strengthening its scope in contract manufacturing as the global customers commend the strengths and dependability of its pharma and biotech sectors.

article thumbnail

Clinical trial packaging services in contract manufacturing for the pharmaceutical industry

Pharmaceutical Technology

Pharmaceutical Technology Has Listed Some of the Leading Providers of Clinical Trial Packaging Services. Download For Free Here.

Packaging 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Contract manufacturing issue holds up Regenxbio’s Duchenne gene therapy trial

BioPharma Reporter

Regenxbio says it is to delay dosing of patients in its DMD gene therapy clinical trial following a quality issue at an unnamed third-party contract manufacturer.

article thumbnail

About the Pharma Contract Manufacturing

Creogenic Pharma

Pharma Contract Manufacturing: From the pharmaceutical sector there is a group of businesses that have tasked themselves to assist other businesses to provide better solutions to customers. When a contract manufacturing company wakes up with a customer in the business, the customer cannot control the jobs the CMO is in control of.

article thumbnail

Sourcing Blockbuster Oncology Products for Clinical Trial Supply

XTalks

This is relevant for clinical trials as more regulators require evidence of efficacy in comparison to the standard of care, which is likely to be one of the blockbuster products. This means that sponsors are having to fork out for these blockbuster products in order to run their trials more often.

article thumbnail

BioSig abandons COVID-19 drug trial on safety concerns

pharmaphorum

US biotech BioSig Technologies has abandoned a phase 2 trial of its antiviral drug merimepodib with Gilead’s Veklury in severe COVID-19 patients, after concluding the safety of the combination was in doubt. However the Grade 3 group had “markedly different outcomes… making it unlikely that the trial would meet its primary safety endpoints.”.

article thumbnail

CAMP4’s funding influx paves the way for tapping regulatory RNA to treat urea cycle disorders

Pharmaceutical Technology

CAMP4’s CSO David Bumcrot PhD tells Pharmaceutical Technology that the company plans to see clinical trials go forward for their urea cycle disorder programs late next year. In preparation for this, drug manufacturing will begin later this year and will be outsourced to external contract manufacturing organisations (CMOs).

RNA 245